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Background
Deficiency of the lysosomal glucocerebrosidase (GCR)
enzyme results in Gaucher disease, the most common
inherited storage disorder [1]. Current treatment con-
sists of enzyme replacement therapy by administration
of exogenous GCR. Although effective, it is exceptionally
expensive [2]. In Brazil, the public healthcare system
provides the drug free of charge for all Gaucher’s
patients, which reaches the order of $84 million per
year. However, the production of GCR by public institu-
tions in Brazil would reduce significantly the therapy
costs. With this purpose, we have previously developed
a cell line producing recombinant GCR using ancho-
rage-dependent CHO cells [3]. Recent advances in cell
culture technology have allowed the elimination of
serum along with the growth of cells in suspension
mode. This mode is preferred in industrial production
due to the well-understood principles of scaling para-
meters and the ease of process control. Additionally, the
serum is expensive and a source of contaminants [4].
Here, we describe the adaptation of a CHO cell line
producing human GCR to suspension culture in serum-
free medium, and evaluate its effects on protein expres-
sion, glycosylation and enzymatic activity.
Methods
Anchorage-dependent CHO cells producing recombi-
nant human GCR in alpha-MEM supplemented with
10% serum were submitted to the process of adaptation
to suspension culture in the chemically defined serum-
free medium CD OptiCHO (Invitrogen). Two different
strategies were used: direct adaptation (complete serum
withdrawal in one passage) and sequential adaptation
(reduction in serum concentration through several cell
passages) in T-25 and T-75 culture flasks (not treated to
avoid cell attachment), and 125 mL erlenmeyer flasks.
Culture supernatants from adapted CHO cell clones
were analyzed for GCR expression, using a murine anti-
human GCR polyclonal antibody [5]. Glycosylation ana-
lysis of secreted GCR was performed by digestion with
the endoglycosidases PNGase F and Endo H, and enzy-
matic activity was determined fluorometrically with the
synthetic substrate 4-MUG.
Results and conclusions
Although being laborious and very time-consuming, the
process of adapting CHO cells producing recombinant
GCR to growth in suspension culture and serum-free
medium was successful. Protein bands of 66-69 kDa cor-
responding to secreted and glycosylated GCR were
detected by western blotting analysis. Surprisingly, direct
adaptation was more effective than sequential adaptation
in obtaining high-producing clones. However, an unex-
pected decreased in the GCR expression was observed in
long-term culture (40 days), indicating the presence of
unstable cells producing GCR. In addition, the secreted
protein was not active in the serum-free suspension cul-
ture, although glycosylation analysis showed a properly
glycosylated GCR containing complex- and hybrid-type
oligosaccharides, consistent with a functional enzyme.
These results suggest that the stable production of an
active GCR by CHO cells may be serum-dependent. The
next steps include the addition of serum in the cell cul-
ture adapted to suspension. To our knowledge, this is the
first report describing an adaptation process of CHO
cells producing GCR for serum-free suspension culture
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